Trial Profile
A Randomized,Double Blind,Placebo-controlled,Parallel Group,Repeat Dose Study of the Safety and Efficacy of REGN475 in Patients With Osteoarthritis of the Knee.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Sep 2015
Price :
$35
*
At a glance
- Drugs Fasinumab (Primary)
- Indications Musculoskeletal pain
- Focus Adverse reactions
- 08 Nov 2010 Preliminary results presented at the 74th Annual Scientific Meeting of the American College of Rheumatology and the 45th Annual Meeting of the Association of Rheumatology Health Professionals.
- 09 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.